Nicotinic acetylcholine receptors play a role in THC dependence, with human genetic confirmation

Specific nicotinic receptor subtypes (alpha3beta4 and alpha6beta4) modulated THC withdrawal in mice, and genetic variations in these same receptor genes were associated with cannabis disorder in humans.

Donvito, Giulia et al.·Addiction biology·2020·Moderate EvidenceAnimal StudyAnimal Study
RTHC-02519Animal StudyModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Alpha3beta4 nAChR antagonist/partial agonist reduced THC withdrawal signs. Alpha5 and alpha6 nAChR knockout mice had decreased withdrawal. Beta2 and alpha7 knockouts showed no change. Human genetic association studies confirmed that variations in genes coding for alpha5, alpha3, beta4, and alpha6 nAChRs were associated with cannabis disorder phenotypes.

Key Numbers

AuIB (alpha3beta4 antagonist) and AT-1001 (alpha3beta4 partial agonist) dose-dependently attenuated THC withdrawal. Alpha5 and alpha6 KO mice: decreased withdrawal. Beta2, alpha7 KO: no change. Human genes: CHRNA5, CHRNA3, CHRNB4, CHRNA6 associated with cannabis disorder.

How They Did This

Multi-approach study: pharmacological challenges in THC-dependent mice, knockout mouse models (alpha5, alpha6, beta2, alpha7 nAChRs), and human genetic association studies for cannabis disorder phenotypes.

Why This Research Matters

This identifies specific nicotinic receptor subtypes as potential medication targets for cannabis dependence, supported by converging evidence from animal pharmacology, knockout genetics, and human genomics.

The Bigger Picture

The nicotinic-cannabinoid system interaction provides a novel therapeutic target class for cannabis dependence, leveraging existing knowledge from nicotine addiction pharmacology.

What This Study Doesn't Tell Us

Animal withdrawal model uses rimonabant-precipitated withdrawal which may not fully match human spontaneous withdrawal; human genetic associations are correlational; specific mechanism of nicotinic-cannabinoid interaction not fully elucidated.

Questions This Raises

  • ?Could existing nicotinic receptor drugs (like varenicline) help with cannabis cessation?
  • ?Would alpha3beta4 partial agonists be effective and tolerable in human cannabis dependence?

Trust & Context

Key Stat:
Mouse pharmacology, knockout genetics, and human genomics converged on the same nicotinic receptor subtypes
Evidence Grade:
Strong converging evidence from three complementary approaches (pharmacology, knockout mice, human genetics).
Study Age:
Published in 2020.
Original Title:
Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies.
Published In:
Addiction biology, 25(1), e12691 (2020)
Database ID:
RTHC-02519

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What do nicotine receptors have to do with cannabis addiction?

This study found that specific nicotinic acetylcholine receptor subtypes modulate THC withdrawal. This means the brain systems involved in nicotine and cannabis dependence overlap, and drugs targeting nicotinic receptors could potentially help with cannabis cessation.

Could this lead to new treatments?

Yes. The convergence of animal and human genetic evidence on specific receptor subtypes (alpha3beta4, alpha6beta4) provides clear targets for medication development. Some existing nicotinic receptor drugs could be candidates for repurposing.

Read More on RethinkTHC

Cite This Study

RTHC-02519·https://rethinkthc.com/research/RTHC-02519

APA

Donvito, Giulia; Muldoon, Pretal P; Jackson, Kia J; Ahmad, Urslan; Zaveri, Nur T; McIntosh, J Michael; Chen, Xiangning; Lichtman, Aron H; Damaj, M Imad. (2020). Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies.. Addiction biology, 25(1), e12691. https://doi.org/10.1111/adb.12691

MLA

Donvito, Giulia, et al. "Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies.." Addiction biology, 2020. https://doi.org/10.1111/adb.12691

RethinkTHC

RethinkTHC Research Database. "Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC d..." RTHC-02519. Retrieved from https://rethinkthc.com/research/donvito-2020-neuronal-nicotinic-acetylcholine-receptors

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.